Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy
Table 1
Baseline characteristics of the chronic hepatitis B patients () treated with telbivudine therapy.
Characteristic
Patients n (%)
Age, years (mean ± SD)
48 ± 13
Gender, male
99 (77)
HBeAg status, positive
46 (36)
Genotype, B/C/unknown
73/23/33
Treatment-naïve
112 (87)
Liver cirrhosis
31 (24)
Hepatic decompensation
20 (16)
Hepatocellular carcinoma
13 (10)
Diabetes mellitus
15 (12)
Hypertension
13 (10)
Contrast-medium exposure
13 (10)
Albumin, g/dL (IQR)
4.3 (4.0–4.5)
Bilirubin, mg/dL (IQR)
0.9 (0.7–1.3)
AST, U/L (IQR)
80 (51–162)
ALT, U/L (IQR)
158 (85–337)
Creatinine (mg/dL) (mean ± SD)
1.06 ± 0.59
CKD-EPI (mL/min/1.73 m2) (mean ± SD)
85.04 ± 18.27
Baseline HBV DNA, log IU/mL (IQR)
5.9 (4.8–7.5)
Baseline HBV DNA > 7 log IU/mL
42 (33)
ALT: alanine transaminase; AST: aspartate transaminase; CKD-EPI: the formula of Chronic Kidney Disease Epidemiology Collaboration; HBeAg: hepatitis B e-antigen; IQR: interquartile range; SD: standard deviation.
